Amiodarone/baricitinib/favipiravirHypothyroidism and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1962卷 / 1期

关键词：

D O I：

10.1007/s40278-023-41695-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：25 / 25

相关论文

共 50 条

[31] Mirtazapine/pregabalinDelirium and off-label use: case report
Reactions Weekly, 2024, 2029 (1) : 384 - 384
[32] DexamethasoneHyperglycaemia following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 173 - 173
[33] FavipiravirNephrotoxicity following off-label use: case report
Reactions Weekly, 2022, 1929 (1) : 283 - 283
[34] BevacizumabRetinal breaks and off-label use: case report
Reactions Weekly, 2022, 1924 (1) : 120 - 120
[35] NivolumabFever following off-label use: case report
Reactions Weekly, 2016, 1601 (1) : 186 - 186
[36] DexamethasoneAspergillosis secondary to off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 177 - 177
[37] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[38] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[39] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[40] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176

← 1 2 3 4 5 →